| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.06 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.06 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.06 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.093 | 0.06 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.06 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.066 | 0.06 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.1 | 0.06 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.06 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.056 | 0.06 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.06 |